Research Progress of Biosimilars of Monoclonal Antibody Drugs For The Treatment of Tumors

Jiahao Qian

doi:10.62051/d2asyr80

Authors

Jiahao Qian

DOI:

https://doi.org/10.62051/d2asyr80

Keywords:

Monoclonal antibodies, biosimilars, cancer targets.

Abstract

Monoclonal antibodies (mAbs) have gained prominence in cancer treatment due to their targeted therapeutic mechanisms, offering fewer side effects compared to traditional chemotherapy. Despite the advancement in original mAb-based anticancer drugs, the high costs associated with these therapies pose a significant challenge, especially for low- and middle-income countries. This has led to an increased focus on developing biosimilars, which are more affordable alternatives with similar therapeutic effects. This paper reviews the research progress of mAb drugs and their biosimilars for tumor treatment, highlighting the clinical impact of mAbs targeting common cancer markers such as HER-2, CD38, and eEF2K. For instance, trastuzumab biosimilars have been shown to improve the pathological complete response rate (pCR) in breast cancer patients when added to neoadjuvant chemotherapy, demonstrating an approximate 15% increase compared to chemotherapy alone. The study concludes that while biosimilars provide a cost-effective and accessible alternative, there is still a lack of long-term clinical data and real-world efficacy, particularly for biosimilars targeting newer cancer markers like CD38 and eEF2K. The paper highlights key advancements in biosimilar production, such as those of trastuzumab biosimilars, and discusses emerging targets like eEF2K, with potential for future therapeutic interventions.

Downloads

Download data is not yet available.

References

[1] Broer, L. N., Knapen, D. G., de Groot, D. J. A., Mol, P. G. M., Kosterink, J. G. W., de Vries, E. G. E., & Lub-de Hooge, M. N. Monoclonal antibody biosimilars for cancer treatment. iScience, 2024, 27: 110115.

[2] Liu, J., Yang, Y., & Gu, L. Advanced research on neoadjuvant therapy with trastuzumab in HER2-positive breast cancer. Chinese Journal of Clinical Oncology, 2014, 41(16): 1065-1068.

[3] Li Wei, Pan Yan, Li Xuejun. Mechanisms of trastuzumab resistance and research on new-generation targeted therapies for HER2-positive breast cancer. Chinese Journal of Clinical Pharmacology, 2014, 30(01): 48-51. doi: 10.13699/j.cnki.1001-6821.2014.01.008.

[4] Matsubara, J., Hirashima, Y., & Yamada, Y. Gan to Kagaku Ryoho. Cancer & Chemotherapy, 2010, 37(8): 1489-1496.

[5] Lam, K. K., Tang, C. L., Tan, E., Wong, S. H., & Cheah, P. Y. KRAS mutation-independent downregulation of MAPK/PI3K signaling in colorectal cancer. Molecular Oncology, 2022, 16(5): 1171-1183.

[6] Jiang, T., Lu, X., Yang, F., Wang, M., Yang, H., & Xing, N. LMTK3 promotes tumorigenesis in bladder cancer via the ERK/MAPK pathway. FEBS Open Bio, 2020, 10(10): 2107–2121.

[7] Asif, H. M., Sultana, S., Ahmed, S., Akhtar, N., & Tariq, M. HER-2 Positive Breast Cancer - a Mini-Review. Asian Pacific Journal of Cancer Prevention: APJCP, 2016, 17(4): 1609–1615.

[8] Zhu, Y., Zhu, X., Tang, C., Guan, X., & Zhang, W. Progress and challenges of immunotherapy in triple-negative breast cancer. Biochimica et Biophysica Acta - Reviews on Cancer, 2021, 1876(2): 188593.

[9] Hunter, F. W., Barker, H. R., Lipert, B., Rothé, F., Gebhart, G., Piccart-Gebhart, M. J., Sotiriou, C., & Jamieson, S. M. F. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. British Journal of Cancer, 2020, 122(5): 603–612.

[10] Xue Feiyuan. Study on marketing strategy of R pharmaceutical's Herceptin in the Chinese market (Master's thesis). Southwestern University of Finance and Economics, 2019.

[11] Xing Yue, Liu Tong, Teng Xue, et al. Pharmacoeconomic evaluation of trastuzumab biosimilars compared with the original drug in the treatment of recurrent or metastatic HER2-positive breast cancer. Chinese Pharmacy, 2024, 35(09): 1113-1117.

[12] Tao Jianfen. Comparative study on the efficacy of Hanquyou vs. Herceptin combined with pertuzumab in neoadjuvant therapy for HER2-positive breast cancer (Master's thesis). Kunming Medical University, 2023.

[13] Krzywdzińska, A., Puła, B., Szymczak, D., Milanowska, A., Szeremet, A., & Jamroziak, K. Immunophenotypic characteristics of bone marrow microenvironment cellular composition at the biochemical progression of multiple myeloma. Journal of Clinical Medicine, 2022, 11(13): 3722.

[14] Gozzetti, A., Ciofini, S., Simoncelli, M., Santoni, A., Pacelli, P., Raspadori, D., & Bocchia, M. Anti CD38 monoclonal antibodies for multiple myeloma treatment. Human Vaccines & Immunotherapeutics, 2022, 18(5): 2052658.

[15] Voorhees, P. M., Kaufman, J. L., Laubach, J., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L. J., Anderson, L. D., Jr, Nathwani, N., Shah, N., Efebera, Y. A., Holstein, S. A., Costello, C., Jakubowiak, A., Wildes, T. M., Orlowski, R. Z., Shain, K. H., Cowan, A. J., … Richardson, P. G. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood, 2020, 136(8): 936–945.

[16] Goldsmith, S. R., Foley, N., & Schroeder, M. A. Daratumumab for the treatment of multiple myeloma. Drugs of Today, 2021, 57(10): 591–605.

[17] Liu Qiliang. eEF2K and Cancer. Chemistry of Life, 2016, 36(05): 633-638.

[18] Zhang, Y., Cheng, Y., Zhang, L., Ren, X., Huber-Keener, K. J., Lee, S., Yun, J., Wang, H. G., & Yang, J. M. Inhibition of eEF-2 kinase sensitizes human glioma cells to TRAIL and down-regulates Bcl-xL expression. Biochemical and Biophysical Research Communications, 2011, 414(1): 129–134.

[19] Zhang Lan, Zhao Yuqian & Liu Bo. Study on the mechanism of action of the novel eEF2K inhibitor BL-EKI03 in inducing autophagy and apoptosis in breast cancer. Chinese Journal of Pharmacology and Toxicology, 2016, 10: 1063.

[20] Li Yumei, Kong Yan, Yu Dayong, Song Yu, Tang Chuan & Shi Liying. Study on homology modeling of eEF2K protein and virtual screening of its inhibitor small molecules. Chinese Pharmacy, 2019, 16: 2199-2205.